Literature DB >> 29253644

Metabolic phenotyping of human atherosclerotic plaques: Metabolic alterations and their biological relevance in plaque-containing aorta.

Sunhee Jung1, Suk-Won Song2, Sak Lee3, Se Hoon Kim4, Soo-Jin Ann5, Eun Jeong Cheon5, Gijong Yi2, Eui-Young Choi6, Seung Hyun Lee3, Hyun-Chel Joo3, Do Hyun Ryu7, Sang-Hak Lee8, Geum-Sook Hwang9.   

Abstract

BACKGROUND AND AIMS: Atherosclerosis is a chronic inflammatory disease characterized by thickening of the arterial wall. However, a limited number of studies have been conducted on metabolic profiling of human aortic tissue.
METHODS: We applied liquid chromatography/mass spectrometry to perform global and targeted profiling of plaque-containing aortic tissue. The aorta samples included plaque-containing (n = 18) and control plaque-free (n = 24) aortic tissue from patients undergoing aortic surgery.
RESULTS: The metabolic patterns of atherosclerotic and control vessels were significantly different. Metabolites in the purine and glutathione pathways showed dysregulation of oxidative stress in plaques, and levels of glucosylceramide, tryptophan, and kynurenine, which are related to inflammation, were also altered. Interestingly, an increased level of quinic acid was observed in plaques (p < 0.000), and we demonstrated an inhibitory effect of quinic acid on inflammatory activation and oxidative stress in macrophages.
CONCLUSIONS: Our study provides insight into the disease mechanism and potential markers of atherosclerosis through comprehensive metabolic profiling of human aortic tissue samples containing plaque.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Lipidomics; Metabolomics; Quinic acid

Mesh:

Substances:

Year:  2017        PMID: 29253644     DOI: 10.1016/j.atherosclerosis.2017.11.034

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Plasma Metabolic Signature of Atherosclerosis Progression and Colchicine Treatment in Rabbits.

Authors:  Mario Augusto Izidoro; Alberto Cecconi; María Isabel Panadero; Jesús Mateo; Joanna Godzien; Jean Paul Vilchez; Ángeles López-Gonzálvez; Jesús Ruiz-Cabello; Borja Ibañez; Coral Barbas; Francisco J Rupérez
Journal:  Sci Rep       Date:  2020-04-27       Impact factor: 4.379

Review 2.  Innovative Approaches to Assess Intermediate Cardiovascular Risk Subjects: A Review From Clinical to Metabolomics Strategies.

Authors:  Aline M A Martins; Mariana U B Paiva; Diego V N Paiva; Raphaela M de Oliveira; Henrique L Machado; Leonardo J S R Alves; Carolina R C Picossi; Andréa T Faccio; Marina F M Tavares; Coral Barbas; Viviane Z R Giraldez; Raul D Santos; Guilherme U Monte; Fernando A Atik
Journal:  Front Cardiovasc Med       Date:  2021-12-22

3.  Upregulated Kynurenine Pathway Enzymes in Aortic Atherosclerotic Aneurysm: Macrophage Kynureninase Downregulates Inflammation.

Authors:  Masanori Nishimura; Atsushi Yamashita; Yunosuke Matsuura; Junichi Okutsu; Aiko Fukahori; Tsuyoshi Hirata; Tomohiro Nishizawa; Hirohito Ishii; Kazunari Maekawa; Eriko Nakamura; Kazuo Kitamura; Kunihide Nakamura; Yujiro Asada
Journal:  J Atheroscler Thromb       Date:  2020-12-10       Impact factor: 4.928

Review 4.  Metabolism in atherosclerotic plaques: immunoregulatory mechanisms in the arterial wall.

Authors:  Maria J Forteza; Daniel F J Ketelhuth
Journal:  Clin Sci (Lond)       Date:  2022-03-31       Impact factor: 6.876

Review 5.  Artificial Intelligence, Machine Learning, and Cardiovascular Disease.

Authors:  Pankaj Mathur; Shweta Srivastava; Xiaowei Xu; Jawahar L Mehta
Journal:  Clin Med Insights Cardiol       Date:  2020-09-09

6.  Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin.

Authors:  Ji Soo Han; Kyu Kim; Youngae Jung; Jae-Hwan Lee; June Namgung; Hae-Young Lee; Jon Suh; Geum-Sook Hwang; Sang-Hak Lee
Journal:  Sci Rep       Date:  2018-10-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.